These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 25723494)

  • 41. Neuropsychological function and cerebral metabolites in HIV-infected youth.
    Nagarajan R; Sarma MK; Thomas MA; Chang L; Natha U; Wright M; Hayes J; Nielsen-Saines K; Michalik DE; Deville J; Church JA; Mason K; Critton-Mastandrea T; Nazarian S; Jing J; Keller MA
    J Neuroimmune Pharmacol; 2012 Dec; 7(4):981-90. PubMed ID: 23065459
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metabolite ratios in the posterior cingulate cortex do not track cognitive decline in Parkinson's disease in a clinical setting.
    Almuqbel M; Melzer TR; Myall DJ; MacAskill MR; Pitcher TL; Livingston L; Wood KL; Keenan RJ; Dalrymple-Alford JC; Anderson TJ
    Parkinsonism Relat Disord; 2016 Jan; 22():54-61. PubMed ID: 26627939
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evidence of reversible axonal dysfunction in systemic lupus erythematosus: a proton MRS study.
    Appenzeller S; Li LM; Costallat LT; Cendes F
    Brain; 2005 Dec; 128(Pt 12):2933-40. PubMed ID: 16195241
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A 1H magnetic resonance spectroscopy study in patients with obstructive sleep apnea.
    Sarchielli P; Presciutti O; Alberti A; Tarducci R; Gobbi G; Galletti F; Costa C; Eusebi P; Calabresi P
    Eur J Neurol; 2008 Oct; 15(10):1058-64. PubMed ID: 18717729
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Single voxel magnetic resonance spectroscopy at 3 Tesla in a memory disorders clinic: early right hippocampal NAA/Cr loss in mildly impaired subjects.
    Caserta MT; Ragin A; Hermida AP; Ahrens RJ; Wise L
    Psychiatry Res; 2008 Nov; 164(2):154-9. PubMed ID: 18930637
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vivo 1H MRS of brain injury and repair during acute SIV infection in the macaque model of neuroAIDS.
    Greco JB; Westmoreland SV; Ratai EM; Lentz MR; Sakaie K; He J; Sehgal PK; Masliah E; Lackner AA; González RG
    Magn Reson Med; 2004 Jun; 51(6):1108-14. PubMed ID: 15170829
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neurometabolic Remodeling in Chronic Hiv Infection: a Five-Year Follow-up Multi-Voxel Mrs Study.
    Boban J; Thurnher MM; Brkic S; Lendak D; Bugarski Ignjatovic V; Todorovic A; Kozic D
    Sci Rep; 2019 Dec; 9(1):19799. PubMed ID: 31875001
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Heterogeneity in neurocognitive change trajectories among people with HIV starting antiretroviral therapy in Rakai, Uganda.
    Rubin LH; Saylor D; Nakigozi G; Nakasujja N; Robertson K; Kisakye A; Batte J; Mayanja R; Anok A; Lofgren SM; Boulware DR; Dastgheyb R; Reynolds SJ; Quinn TC; Gray RH; Wawer MJ; Sacktor N
    J Neurovirol; 2019 Dec; 25(6):800-813. PubMed ID: 31218522
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HIV infection and latency induce a unique metabolic signature in human macrophages.
    Castellano P; Prevedel L; Valdebenito S; Eugenin EA
    Sci Rep; 2019 Mar; 9(1):3941. PubMed ID: 30850623
    [TBL] [Abstract][Full Text] [Related]  

  • 50. White matter microstructure among perinatally HIV-infected youth: a diffusion tensor imaging study.
    Sarma MK; Keller MA; Macey PM; Michalik DE; Hayes J; Nielsen-Saines K; Deville J; Church JA; Walot I; Albert Thomas M
    J Neurovirol; 2019 Jun; 25(3):313-323. PubMed ID: 30610741
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir.
    Robertson K; Maruff P; Ross LL; Wohl D; Small CB; Edelstein H; Shaefer MS
    J Neurovirol; 2019 Feb; 25(1):22-31. PubMed ID: 30298202
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose.
    Calcagno A; Barco A; Trunfio M; Bonora S
    Curr HIV/AIDS Rep; 2018 Feb; 15(1):84-91. PubMed ID: 29363025
    [TBL] [Abstract][Full Text] [Related]  

  • 53. White matter measures are near normal in controlled HIV infection except in those with cognitive impairment and longer HIV duration.
    Cysique LA; Soares JR; Geng G; Scarpetta M; Moffat K; Green M; Brew BJ; Henry RG; Rae C
    J Neurovirol; 2017 Aug; 23(4):539-547. PubMed ID: 28324319
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pilot Assessment of Brain Metabolism in Perinatally HIV-Infected Youths Using Accelerated 5D Echo Planar J-Resolved Spectroscopic Imaging.
    Iqbal Z; Wilson NE; Keller MA; Michalik DE; Church JA; Nielsen-Saines K; Deville J; Souza R; Brecht ML; Thomas MA
    PLoS One; 2016; 11(9):e0162810. PubMed ID: 27622551
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evolution of changes in cognitive function after the initiation of antiretroviral therapy.
    Mora-Peris B; Stevens E; Ferretti F; Underwood J; Taylor S; Winston A
    AIDS Res Ther; 2016; 13():20. PubMed ID: 27081393
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Differences in the direction of change of cerebral function parameters are evident over three years in HIV-infected individuals electively commencing initial cART.
    Winston A; Puls R; Kerr SJ; Duncombe C; Li P; Gill JM; Ramautarsing R; Taylor-Robinson SD; Emery S; Cooper DA;
    PLoS One; 2015; 10(2):e0118608. PubMed ID: 25723494
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study.
    Winston A; Duncombe C; Li PC; Gill JM; Kerr SJ; Puls R; Petoumenos K; Taylor-Robinson SD; Emery S; Cooper DA;
    Clin Infect Dis; 2010 Mar; 50(6):920-9. PubMed ID: 20146627
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Two patterns of cerebral metabolite abnormalities are detected on proton magnetic resonance spectroscopy in HIV-infected subjects commencing antiretroviral therapy.
    Winston A; Duncombe C; Li PC; Gill JM; Kerr SJ; Puls RL; Taylor-Robinson SD; Emery S; Cooper DA;
    Neuroradiology; 2012 Dec; 54(12):1331-9. PubMed ID: 22772471
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differences in the variability of cerebral proton magnetic resonance spectroscopy (1H-MRS) measurements within three HIV-infected cohorts.
    Vigneswaran S; Rojas JH; Garvey L; Taylor-Robinson S; Winston A
    Neuroradiol J; 2015 Dec; 28(6):545-54. PubMed ID: 26493269
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of metabolic changes within the normal appearing gray and white matters in neurologically asymptomatic HIV-1-positive and HCV-positive patients: magnetic resonance spectroscopy and immunologic correlation.
    Bladowska J; Zimny A; Kołtowska A; Szewczyk P; Knysz B; Gąsiorowski J; Furdal M; Sąsiadek MJ
    Eur J Radiol; 2013 Apr; 82(4):686-92. PubMed ID: 23246331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.